Market Overview

Benzinga's Top Upgrades, Downgrades For June 1, 2020

Share:

Upgrades

  • Guggenheim changed the rating for Macrogenics Inc (NASDAQ: MGNX) from Neutral to Buy. For the first quarter, Macrogenics had an EPS of ($0.91), compared to year-ago quarter EPS of ($0.99). The stock has a 52-week-high of $29.50 and a 52-week-low of $4.04. Macrogenics's stock last closed at $19.24 per share.
  • DA Davidson changed the rating for FormFactor Inc (NASDAQ: FORM) from Neutral to Buy. In the first quarter, FormFactor showed an EPS of $0.33, compared to $0.20 from the year-ago quarter. The stock has a 52-week-high of $28.58 and a 52-week-low of $14.20. FormFactor's stock last closed at $25.17 per share.
  • JP Morgan upgraded the stock for Keysight Technologies Inc (NYSE: KEYS) from Neutral to Overweight. Keysight Technologies earned $0.78 in the second quarter, compared to $1.22 in the year-ago quarter. The stock has a 52-week-high of $110.00 and a 52-week-low of $71.03. Keysight Technologies's stock last closed at $108.15 per share.
  • Citigroup changed the rating for Apergy Corp (NYSE: APY) from Neutral to Buy. In the first quarter, Apergy showed an EPS of $0.04, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $34.80 and a 52-week-low of $2.89. Apergy's stock last closed at $9.05 per share.
  • For Teva Pharmaceutical Industries Ltd (NYSE: TEVA), SunTrust Robinson Humphrey upgraded the stock from Hold to Buy. For the first quarter, Teva Pharmaceutical Indus had an EPS of $0.76, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $13.76 and a 52-week-low of $6.07. Teva Pharmaceutical Indus's stock last closed at $12.53 per share.
  • JP Morgan upgraded the stock for Viavi Solutions Inc (NASDAQ: VIAV) from Neutral to Overweight. In the third quarter, Viavi Solutions showed an EPS of $0.14, compared to $0.13 from the year-ago quarter. The stock has a 52-week-high of $16.35 and a 52-week-low of $8.08. Viavi Solutions's stock last closed at $11.59 per share.
  • JP Morgan changed the rating for Hess Corp (NYSE: HES) from Neutral to Overweight. For the first quarter, Hess had an EPS of ($0.60), compared to year-ago quarter EPS of $0.09. The stock has a 52-week-high of $74.11 and a 52-week-low of $26.06. Hess's stock last closed at $47.47 per share.

 

Downgrades

  • Benchmark changed the rating for NextCure Inc (NASDAQ: NXTC) from Buy to Hold. For the first quarter, NextCure had an EPS of $0.33, compared to year-ago quarter EPS of ($4.46). The stock has a 52-week-high of $109.00 and a 52-week-low of $13.86. NextCure's stock last closed at $31.21 per share.
  • Deutsche Bank downgraded the stock for Vail Resorts Inc (NYSE: MTN) from Buy to Hold. Vail Resorts earned $5.04 in the second quarter, compared to $5.02 in the year-ago quarter. The stock has a 52-week-high of $255.37 and a 52-week-low of $125.00. Vail Resorts's stock last closed at $198.57 per share.
  • For Harmonic Inc (NASDAQ: HLIT), JP Morgan downgraded the stock from Overweight to Neutral. For the first quarter, Harmonic had an EPS of ($0.10), compared to year-ago quarter EPS of ($0.05). The stock has a 52-week-high of $8.57 and a 52-week-low of $4.44. Harmonic's stock last closed at $5.39 per share.
  • Jefferies downgraded the stock for CytomX Therapeutics Inc (NASDAQ: CTMX) from Buy to Hold. CytomX Therapeutics earned $0.26 in the first quarter, compared to ($0.31) in the year-ago quarter. The stock has a 52-week-high of $15.44 and a 52-week-low of $3.60. CytomX Therapeutics's stock last closed at $8.86 per share.
  • ScotiaBank changed the rating for Occidental Petroleum Corp (NYSE: OXY) from Sector Outperform to Sector Perform. In the first quarter, Occidental Petroleum showed an EPS of ($0.52), compared to $0.84 from the year-ago quarter. The stock has a 52-week-high of $54.05 and a 52-week-low of $9.00. Occidental Petroleum's stock last closed at $12.97 per share.

 

Initiations

  • With a rating of Buy, Goldman Sachs initiated coverage on Becton, Dickinson and Co (NYSE: BDX). The price target is set at $278.00 for Becton, Dickinson. For the second quarter, Becton, Dickinson had an EPS of $2.55, compared to year-ago quarter EPS of $2.59. The stock has a 52-week-high of $286.72 and a 52-week-low of $197.75. Becton, Dickinson's stock last closed at $246.97 per share.
  • With a rating of Buy, B. Riley FBR initiated coverage on Drive Shack Inc (NYSE: DS). The price target is set at $4.00 for Drive Shack. Drive Shack earned ($0.28) in the first quarter, compared to ($0.24) in the year-ago quarter. The stock has a 52-week-high of $5.31 and a 52-week-low of $0.86. Drive Shack's stock last closed at $1.78 per share.
  • JP Morgan initiated coverage on CarMax Inc (NYSE: KMX) with an Overweight rating. The price target for CarMax is set at $105.00. CarMax earned $1.30 in the fourth quarter, compared to $1.13 in the year-ago quarter. The stock has a 52-week-high of $103.18 and a 52-week-low of $37.59. CarMax's stock last closed at $88.10 per share.
  • With a rating of Equal-Weight, Stephens & Co. initiated coverage on S&T Bancorp Inc (NASDAQ: STBA). The price target is set at $27.50 for S&T Bancorp. In the first quarter, S&T Bancorp showed an EPS of $0.39, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $41.53 and a 52-week-low of $18.97. S&T Bancorp's stock last closed at $22.24 per share.
  • With a rating of Buy, HC Wainwright & Co. initiated coverage on RAPT Therapeutics Inc (NASDAQ: RAPT). The price target is set at $40.00 for RAPT Therapeutics. For the first quarter, RAPT Therapeutics had an EPS of ($0.56), compared to year-ago quarter EPS of ($13.28). The stock has a 52-week-high of $51.21 and a 52-week-low of $10.52. RAPT Therapeutics's stock last closed at $18.28 per share.
  • With a rating of Buy, HC Wainwright & Co. initiated coverage on Allena Pharmaceuticals Inc (NASDAQ: ALNA). The price target is set at $10.00 for Allena Pharmaceuticals. In the first quarter, Allena Pharmaceuticals showed an EPS of ($0.31), compared to ($0.55) from the year-ago quarter. The stock has a 52-week-high of $6.30 and a 52-week-low of $0.53. Allena Pharmaceuticals's stock last closed at $1.68 per share.
 

Related Articles (APY + ALNA)

View Comments and Join the Discussion!

Posted-In: Initiations top upgradesPenny Stocks Upgrades Downgrades Initiation Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
BKHMizuhoMaintains70.0
JOBAlliance Global PartnersUpgrades2.5
RARECanaccord GenuityMaintains91.0
TTDOppenheimerMaintains450.0
PYPLWedbushMaintains200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com